CAR T-Cell Therapy Market By Drug type, By Indication, By End user : Global Opportunity Analysis and Industry Forecast, 2023?2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "CAR T-Cell therapy Market," The car t-cell therapy market was valued at $1.7 billion in 2021, and is estimated to reach $6.1 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031. Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment. CAR T-cell therapy is a type of cell-based gene therapy, because it involves altering the genes inside T-cells to help them attack the cancer. T-cells are part of the immune system. They are a type of white blood cell with proteins on the surface that act as receptors.

Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment. During this treatment, healthcare professionals reprogram the immune system to attack cancer cells. CAR T-cell therapy is a type of cell-based gene therapy, because it involves altering the genes inside T-cells to help them attack the cancer. T-cells are part of the immune system. They are a type of white blood cell with proteins on the surface that act as receptors. Healthcare professionals currently use CAR T-cell therapy to treat various types of cancer.

The CAR T-cell therapy market will show significant market growth during the forecast period owing to rise in prevalence of cancer, rise in demand for ideal therapeutics for treatment of cancer, and favorable reimbursement policies provided by manufacturers & insurance providers in some countries. However, higher cost of treatment, and stringent government regulation for approval of these therapeutics are expected to hamper the market growth. Furthermore, promising drugs in pipeline, expected approval of newer CART therapeutics, rise in number of target population with lack of ideal treatment, and surge in awareness regarding CART therapies are expected to significantly drive the market growth during the forecast period. In addition, technological advancements, launch of various products, and strategies among the key players such as acquisition, collaboration, and agreement drive the CAR T-cell therapy market growth.

The CAR T-cell therapy market is segmented on the basis of drug type, indication, end user, and region. On the basis of drug type, the market is classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others. By indication, the market is segregated into lymphoma, acute lymphocytic leukemia, and others. Depending on end user, it is fragmented into hospitals and cancer treatment centers.

The CAR T-cell therapy market is studied across North America (the U.S., and Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

The major players profiled in the report are: Autolus, Bluebird Bio-Inc., Bristol-Myers Squibb, Caribou Biosciences Inc., Cartesian Therapeutics, Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Merck & Co. Inc., Miltenyi Biotech, Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the car t-cell therapy market analysis from 2021 to 2031 to identify the prevailing car t-cell therapy market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the car t-cell therapy market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global car t-cell therapy market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Go To Market Strategy
New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Average Selling Price Analysis / Price Point Analysis
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis

Key Market Segments

By Drug type

Axicabtagene Ciloleucel
Tisagenlecleucel
Brexucabtagene Autoleucel
Others

By Indication

Lymphoma
Acute Lymphocytic Leukemia
Others

By End user

Hospitals
Cancer Treatment Centers

By Region

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Rest of Europe
Asia-Pacific
- Japan
- China
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East And Africa

Key Market Players:

Autolus Therapeutics
Bluebird Bio, Inc.
Bristol-Myers Squibb
Caribou Biosciences, Inc.
Cartesian Therapeutics, Inc.
Celgene Corporation
Cellectis
Celyad Oncology
Gilead Sciences, Inc. (Kite Pharma Inc.)
Intellia Therapeutics
Juno Therapeutics, Inc.
Merck & Co., Inc.
Miltenyi Biotech
Novartis AG
Pfizer, Inc.
Sorrento Therapeutics, Inc.

Product Code: A16971

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Surge in prevalence of cancer
  - 3.4.1.2. Rise in awareness regarding CAR T-cell therapy
  - 3.4.1.3. Increase in demand of ideal therapeutics for treatment of cancer

3.4.2. Restraints
- 3.4.2.1. High cost of CAR T-cell therapies
- 3.4.2.2. Strict government regulation for approval of drugs

3.4.3. Opportunities
- 3.4.3.1. Increase in R&D activities to develop CAR T-cell therapeutics

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CAR T-CELL THERAPY MARKET, BY DRUG TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Axicabtagene Ciloleucel
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Tisagenlecleucel
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Brexucabtagene Autoleucel
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country

CHAPTER 5: CAR T-CELL THERAPY MARKET, BY INDICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Lymphoma
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Acute Lymphocytic Leukemia
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: CAR T-CELL THERAPY MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Cancer Treatment Centers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country

CHAPTER 7: CAR T-CELL THERAPY MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drug type
- 7.2.3. Market size and forecast, by Indication
- 7.2.4. Market size and forecast, by End user
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Drug type
  - 7.2.5.1.3. Market size and forecast, by Indication
  - 7.2.5.1.4. Market size and forecast, by End user
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Drug type
  - 7.2.5.2.3. Market size and forecast, by Indication
  - 7.2.5.2.4. Market size and forecast, by End user
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drug type
- 7.3.3. Market size and forecast, by Indication
- 7.3.4. Market size and forecast, by End user
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Drug type
  - 7.3.5.1.3. Market size and forecast, by Indication
  - 7.3.5.1.4. Market size and forecast, by End user
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Drug type
  - 7.3.5.2.3. Market size and forecast, by Indication
  - 7.3.5.2.4. Market size and forecast, by End user
  - 7.3.5.3. U.K.
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Drug type
  - 7.3.5.3.3. Market size and forecast, by Indication
  - 7.3.5.3.4. Market size and forecast, by End user
  - 7.3.5.4. Rest of Europe
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Drug type
  - 7.3.5.4.3. Market size and forecast, by Indication
  - 7.3.5.4.4. Market size and forecast, by End user
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drug type
- 7.4.3. Market size and forecast, by Indication
- 7.4.4. Market size and forecast, by End user
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Drug type
  - 7.4.5.1.3. Market size and forecast, by Indication
  - 7.4.5.1.4. Market size and forecast, by End user
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Drug type
  - 7.4.5.2.3. Market size and forecast, by Indication
  - 7.4.5.2.4. Market size and forecast, by End user
  - 7.4.5.3. Rest of Asia-Pacific
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Drug type
  - 7.4.5.3.3. Market size and forecast, by Indication
  - 7.4.5.3.4. Market size and forecast, by End user
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drug type
- 7.5.3. Market size and forecast, by Indication
- 7.5.4. Market size and forecast, by End user
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Latin America
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Drug type
  - 7.5.5.1.3. Market size and forecast, by Indication
  - 7.5.5.1.4. Market size and forecast, by End user
  - 7.5.5.2. Middle East And Africa
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Drug type
  - 7.5.5.2.3. Market size and forecast, by Indication
  - 7.5.5.2.4. Market size and forecast, by End user

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. Autolus Therapeutics
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
9.2. Bluebird Bio, Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Bristol-Myers Squibb
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Caribou Biosciences, Inc.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
9.5. Cartesian Therapeutics, Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
9.6. Celgene Corporation
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
9.7. Cellectis
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Celyad Oncology
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Key strategic moves and developments
9.9. Gilead Sciences, Inc. (Kite Pharma Inc.)
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Intellia Therapeutics
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
9.11. Juno Therapeutics, Inc.
- 9.11.1. Company overview
- 9.11.2. Key Executives
- 9.11.3. Company snapshot
- 9.11.4. Operating business segments
- 9.11.5. Product portfolio
9.12. Merck & Co., Inc.
- 9.12.1. Company overview
- 9.12.2. Key Executives
- 9.12.3. Company snapshot
- 9.12.4. Operating business segments
- 9.12.5. Product portfolio
- 9.12.6. Business performance
9.13. Miltenyi Biotech
- 9.13.1. Company overview
- 9.13.2. Key Executives
- 9.13.3. Company snapshot
- 9.13.4. Operating business segments
- 9.13.5. Product portfolio
9.14. Novartis AG
- 9.14.1. Company overview
- 9.14.2. Key Executives
- 9.14.3. Company snapshot
- 9.14.4. Operating business segments
- 9.14.5. Product portfolio
- 9.14.6. Business performance
9.15. Pfizer, Inc.
- 9.15.1. Company overview
- 9.15.2. Key Executives
- 9.15.3. Company snapshot
- 9.15.4. Operating business segments
- 9.15.5. Product portfolio
- 9.15.6. Business performance
9.16. Sorrento Therapeutics, Inc.
- 9.16.1. Company overview
- 9.16.2. Key Executives
- 9.16.3. Company snapshot
- 9.16.4. Operating business segments
- 9.16.5. Product portfolio
- 9.16.6. Business performance